Top

Published in:

01-01-2010

Newer anticoagulants in 2009

Authors: Meyer Michel Samama, Grigoris T. Gerotziafas

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2010

Abstract

Several newer anticoagulants are under clinical development. Recently two of them, Dabigatran etexilate/Pradaxa^®. and Rivaroxaban/Xarelto^® obtained marketing authorization in Europe and Canada for the prevention of thromboembolic events following major orthopedic surgery such as total hip and knee replacement. The results of Phase III clinical studies in thromboprophylaxis in major orthopedic surgery are highlighted and discussed in detail. Ongoing Phase II and III clinical trials assess their efficacy in the secondary prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the long-term prevention of stroke in patients with non-valvular atrial fibrillation and in combination with aspirin and clopidogrel in patients with acute coronary syndromes. Many other small antithrombotic molecules including a new generation of low molecular weight heparins, are currently in different stages of clinical development. In addition to being administered orally, the newer anticoagulant agents have a more balanced benefit/risk ratio and wider therapeutic window. They have a rapid onset of action, a predictable anticoagulant effect that does not require routine laboratory monitoring. They have minor food and drug interactions, including those with cytochrome P450 and P.gp. They are highly specific and targeted to a single coagulation factor, and could carry similar or less hemorrhagic risks compared to the older anticoagulant agents. Finally, they may be used in a broader variety of patients, especially the medically ill patients with advanced cancer, and the elderly without any dosage adjustment, regardless of the patient age, gender, body weight, or in patients with mild renal impairment. Their use in the general world will hopefully confirm the promising results of clinical trials.

Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI (2008) American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines (8th edn) Chest 141S-159S

Greinacher A (2009) Heparin-induced thrombocytopenia. J Thromb Haemost 7(suppl 1):9–12CrossRefPubMed

Weitz JI, Hirsh J, Samama MM (2008) New antithrombotic drugs. The eighth ACCP conference on antithrombotic and thrombolytic therapy. Chest 133:234S–256SCrossRefPubMed

Turpie AG (2008) New oral anticoagulants in atrial fibrillation. Eur Heart J 29:155–165CrossRefPubMed

Samama MM, Gerotziafas G (2007) Les nouveaux anticoagulants. Ann Pharm 65:8585–8594

Weitz JI, Ansell J (2007) Factor Xa or thrombin: is thrombin a better target. J Thromb Haemost 5:60–67CrossRef

Wong PC, Watson CA, Crain EJ (2008) Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost 6:1736–1741CrossRefPubMed

Samama MM, Le Flem L, Guinet C, Depasse F, Perzborn E, Van Ryn J (2008) Comparative responses of some clotting assays to fondaparinux, dabigatran and rivaroxaban. Pathophysiology of haemostasis and thrombosis, 20th international congress on thrombosis—athens, 25–28 June 2008, p 98 (abstract)

Rezaie AR (2003) DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism on inhibition and comparison with therapeutic heparins. Thromb Haemost 89:112–121PubMed

10.

Perzborn E, Strassburger J, Wilmen A, Pohlman J, Roehrig S, Schlemmer KH, Straub A (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939: an oral, direct factor Xa inhibitor. J Thromb Haemost 3:514–521CrossRefPubMed

11.

Gerotziafas G, Samama MM (2005) Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des 11:3855–3876CrossRefPubMed

12.

Hérault JP, Cappelle M, Bernat A, Millet L, Bono F, Schaeffer P, Herbert JM (2003) Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo. J Thromb Haemos 1:1959–1965CrossRef

13.

Hérault JP, Bernat A, Pflieger AM, Lormeau JC, Herbert JM (1997) Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 283:16–22PubMed

14.

Depasse F, Busson J, Mnich J et al (2005) Effect of BAY 59–7939—a novel, oral, direct factor Xa inhibitor on clot-bound factor Xa activity in vitro. J Thromb Haemost 3(Suppl 1):P1104 Abstract

15.

Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, Harder S (2007) Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 47:1398–1407CrossRefPubMed

16.

Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, Sheth S (2005) Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 28:351–370CrossRefPubMed

17.

Eriksson BI, Dahl OE, Büller HR, Haas SK, Huisman MV, Kakkar AK et al (2005) A New oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaprin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO in randomized trial. J Thromb Haemost 3:103–111CrossRefPubMed

18.

Turpie AGG, Fischer WD, Bauer K, Kwong L, Gent M, Misselwitz F, for the ODIXa-KNEE investigators (2005) An oral, direct factor Xa inhibitor–BAY 59–7939–for prophylaxis against venous thromboembolism after total knee replacement: a dose-ranging study. J Thromb Haemost 3:2479–2486CrossRefPubMed

19.

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Mühlhofer E, Dierig C, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators (2006) A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement. Circulation 114:2313–2316CrossRef

20.

Harenberg J (2008) Development of new anticoagulants: present and future. Semin Thromb Hemost 34:779–793CrossRefPubMed

21.

Bounameaux H (2009) The novel anticoagulants: entering a new era. Swiss Med Wkly 7–139:60–64

22.

Gray A, Hoppensteadt D, Jeske W, Walenga JM, Fareed J (2009) AVE5026: a new hemisynthetic ultra low molecular weight heparin with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis. J Thromb Haemost 7(suppl 2): abst PP-WE-481, 474

23.

Antonijoan RM, Rico S, Puntes M, Borrell M, Fontcuberta J, Monreal M, Martinez-Gonzalez J, Barbanoj MJ (2009) Pharmacokinetics and safety of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers—a first time in human (FTIH) single ascending dose study. J Thromb Haemost 7(suppl 2): abst PP-WE-178, 370

24.

Lassen MR, Dahl OE, Mismetti P, Destrées D, Turpie AGG (2009) AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery–TEEK: a dose-ranging study. J Thromb Haemost 7:566–572CrossRefPubMed

25.

Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J (1997) Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 86:1636CrossRef

26.

Samama MM (2003) Prévention de la maladie thromboembolique veineuse après chirurgie orthopédique majeure: état des lieux et place d’un inhibiteur synthétique et spécifique du facteur Xa. Rev Chir Orthop Réparatrice Appar Mot 89:712–724PubMed

27.

Büller HR, Davidson BL, Decousus H, Gallux A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, MATISSE Lensing AW Investigators (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis MATISSE DVT. Ann Intern Med 140:867–873PubMed

28.

The MATISSE Investigators (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695–1702CrossRef

29.

Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, PEGASUS Investigators (2005) Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92:1212–1220CrossRefPubMed

30.

Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JF, ARTEMIS Lensing AW Investigators (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 322:328–329

31.

Fareed J (2004) Idraparinux sodium sanofi-aventis. Drugs 11:1028–1034

32.

AMADEUS Investigators, Bousser MG, Bouthier J, Büller HR, Cohen AT, Crijns H, Davidson BL, Halperin J, Hankey G, Levy S, Pengo V, Prandoni P, Prins MH, Tomkowski W, Torp-Pedersen C, Wyse DG (2008) Comparison of Idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371:315–321CrossRefPubMed

33.

PERSIST Investigators (1998) A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in DVT: a phase II evaluation. Blood 100:301 Abstract

34.

Harenberg J, Jörg I, Vukojevic Y, Mikus G, Weiss C (2008) Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the Van Gogh trials. Eur J Clin Pharmacol 64:555–563CrossRefPubMed

35.

Trellu M, Perez Y, Ortiz J, Cheng S, Paty I (2009) Bioquipotency of idraparinux and biotinylated Idraparinux after single dose in healthy subjects. J Thromb Haemost 7(suppl 2):abst OC-WE-006, 201

36.

Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M (1995) DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 74:635–639PubMed

37.

Becker RC, Alexander J, Dyke CK, Harrington RA (2004) Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost 92:1182–1193PubMed

38.

Paccaly A, Frixk A, Ozoux ML, Chy V, Rosenburg R, Hinder M, Shukla U, Jensen BK (2006) Pharmacokinetic/pharmacodynamic relationships for Otamixaban, a direct factor Xa Inhibitor, in healthy Subjects. J Clin Pharmacol 46:45–51CrossRefPubMed

39.

Helft G, Leger P (2009) What’s new on antithrombotics in 2007? Ann Cardiol Angeiol 58(4):203–207CrossRef

40.

Bonello L, de Labriolle A, Roy P, Steinberg DH, Pinto Slottow TL, Xue Z, Kaneshige K, Torguson R, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R (2009) Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty. Cardiovasc Revasc Med 10:156–161CrossRefPubMed

41.

Eriksson BI, Quinlan DJ, Weitz JI (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 48:1–22CrossRefPubMed

42.

Shantsila E, Gy L (2008) Apixaban, an oral, direct inhibitor of activated factor Xa. Curr Opin Investig Drugs 9:1020–1023PubMed

43.

Furugohiri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T (2008) DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6:1542–1549

44.

Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412–421CrossRefPubMed

45.

Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939—an oral, direct factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880CrossRefPubMed

46.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Muehlhofer E, Misselwitz F, Geerts W, RECORD 1 Study group (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775CrossRefPubMed

47.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG, RECORD 3 Investigators (2008) Rivaroxaban versus Enoxaparin for thrombo-prophylaxis after knee arthroplasty. N Engl J Med 358:2776–2786CrossRefPubMed

48.

Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD, RECORD 4 Investigators (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial. Lancet 373:1673–1680CrossRefPubMed

49.

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD 2 Investigators (2008) Extended duration Rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 372:31–39CrossRefPubMed

50.

Hull RD, Yusen RD, Bergvist D (2009) Variation in major bleeding definitions in phase III orthopedic VTE prophylaxis trials and the impact on major bleeding frequency. J Thromb Haemost 7 (suppl 2):abst OC-TU-021, 171

51.

Hull RD, Yusen R, Bergqvist D (2009) Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 15(4):377–388CrossRefPubMed

52.

Turpie AGG, Lassen, MR, Kakkar AK, Reiksson I, Gent M (2009) Pooled analysis of four rivaroxaban studies: effects on symptomatic events and bleeding. J Thromb Haemost 7(suppl 1):abst OC-WE-004

53.

Van Thiel DH, Kalodiki E, Wahi R, Litinas E, Haque W, Rao G (2009) Interpretation of benefit-risk of enoxaparin as comparator in the record program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 15(4):389–394CrossRefPubMed

54.

Mega JL, Brauwald S, Mohanavelu P, Burton P, Poulter R, Misselwitz V, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, ACS-TIMI on behalf of the ATLAS 46 study group (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized double-blind, phase II trial. Lancet 374:29–38CrossRefPubMed

55.

56.

Samama MM, Le Flem L, Guinet C et al (2009) Effects of the novel, oral, direct factor Xa inhibitor Rivaroxaban on coagulation assays. J Thromb Haemost 7(suppl 2):377

57.

Samama MM, Le Flem L, Guinet C, Perzborn E, Martinoli JL, Depasse F (2009) Effects of Rivaroxaban, a novel, oral, direct factor Xa inhibitor, on coagulation assays. BJH abst n°89, April 2009

58.

Reghavan N, Frost CE, Yu Z, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81CrossRef

59.

Lassen MR, Davidson BL, Gallus A, Ponco G, Ansell J, Deitchman D (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. Thromb Haemost 5:2368–2375CrossRef

60.

Lassen MR, Gallus A, Pineo GFP, Raskob GE, and the ADVANCE 1 Investigators (2008) Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: the ADVANCE-1 trial. 50th annual meeting and exposition, San Francisco 2008 (abstract 31)

61.

Lassen MR, Gallus AS, Pineo GF, Raskob GE (2009) Late breaking clinical trial: the ADVANCE 2 study: a randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement. J Thromb Haemost 7(suppl 2): abst LB-MO-005, 2

62.

APPRAISE Steering Committee Investigators (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation 119:2877–2885CrossRef

63.

Buller HR, Lensing AWA, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A, EINSTEIN-DVT Dose-Ranging Study Investigators (2008) A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein DVT dose-ranging study. Blood 112:2242–2247CrossRefPubMed

64.

On behalf of the BOTTICELLI investigators, the writing committee, Buller H, Deitchman D, Prins M, Segers A (2008) Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 6:1313–1318CrossRefPubMed

65.

Fuji T, Fujota S, Tachibana S, Kawai Y (2008) Randomized, double-blind, multi-dose efficacy, safety and biomarker study of the oral inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patient after total knee arthroplasty. 50th annual meeting and exposition, San Francisco 2008 (abstract 34)

66.

Lu G, DeGuzman FR, Lakhotia S, Hollenbach SJ, Philipps DR (2008) Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. 50th annual meeting and exposition, San Francisco 2008 (abstract 983)

67.

Turpie AGG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, DD Gretler for the EXPERT Study Group (2009) A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 101:68–76PubMed

68.

Di Nisio M, Middeldorp S, Büller HR (2005) Drug therapy: direct thrombin inhibitors. N Engl J Med 353:1028–1040CrossRefPubMed

69.

Sanford M, Plosker GL (2008) Dabigatran etexilate. Drugs 68:1699–1709CrossRefPubMed

70.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, Van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, RE-MODEL Büller HR Study group (2007) Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178–2185CrossRefPubMed

71.

RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA (2009) The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1–9PubMed

72.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, Van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR, RE-NOVATE Study Group (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 370:949–956CrossRefPubMed

73.

Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI (2009) Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 101:77–85PubMed

74.

Borris LC (2009) Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. Arch Orthop Trauma Surg (in press)

75.

Eikelboom JE, Weitz JI (2009) Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost 101:2–4PubMed

76.

Dahl OE, Kurth AA, Rosencher N, Clemens A, Feuring M, Noack H, Eriksson E (2009) Dabigatran etexilate 150 mg once daily for the prevention of venous thromboembolism after total knee of hip replacement surgery in the elderly and those with moderate renal impairment. J Thromb Haemost 7(suppl 2): abst PP-WE-205, 379

77.

Dahl OE, Francis C, Kurth A, Rosencher N, Feuring M, Clemens A, Noack H, Eriksson I, Caprini JA (2009) In patients predisposed to cardiovascular events, standard doses of dabigatran etexilate prevent post-operative venous thromboembolism effectively and with a good safety profile. J Thromb Haemost 7(suppl 2): abst PP-TH-169, 674

78.

Rosencher N, Noack H, Feuring M, Clemens A, Riedman R, Eriksson I (2009) Type of anaesthesia did not affect the efficacy and safety profile of dabigatran etexilate compared with enoxaparin for primary venous thromboembolism prevention followed total knee or hip replacement surgery. J Thromb Haemost 7(suppl 2): abst PP-TH-167, 673

79.

Harenberg J, Kakkar A, Bergqvist D, Barrowcliffe T, Casu B, Fareed J, Mismetti P, Ofosu FA, Raake W, Samama M, Schulman S, Subcommittee on Control of Anticoagulation of the SSC of the ISTH (2009) Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost 7:1218–1221CrossRef

Title: Newer anticoagulants in 2009
Authors: Meyer Michel Samama
Grigoris T. Gerotziafas
Publication date: 01-01-2010
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 1/2010
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-009-0392-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Thyroid-associated autoimmune coagulation disorders

Association of three polymorphisms selected from a genome-wide association study with coronary heart disease in the Tunisian population

Factor Xa-like and fibrin(ogen)olytic activities of a serine protease from Hippasa agelenoides spider venom gland extract

Interatrial thrombus-in-transit resulting in paradoxical thromboembolism

Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease

The inhibition in tumor necrosis factor-α-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-κB and reactive oxygen species

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials